MedTrace Logo

PF-06741086 Multiple Dose Study in Severe Hemophilia

NCT02974855 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2019-12-04

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.

Conditions

  • Hemophilia A or B

Interventions

BIOLOGICAL

PF-06741086

PF-06741086 subcutaneous (SC) injection

BIOLOGICAL

PF-06741086

PF-06741086 SC injection

BIOLOGICAL

PF-06741086

PF-06741086 SC injection

BIOLOGICAL

PF-06741086

PF-06741086 SC injection

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-08
Primary Completion
2018-12-03
Completion
2018-12-03
FDA Drug
Yes

Countries

  • United States
  • Chile
  • Croatia
  • Poland
  • South Africa
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02974855 on ClinicalTrials.gov